Specialty Generics Market Size, Share & Trends Analysis By Type (Injectables, Oral Drugs), By Application (Oncology, Inflammatory Conditions, Hepatitis C), By End-use (Specialty, Retail), By Region, and Segment- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global specialty generics market size was estimated at USD 70.19 billion in 2022 and is expected to surpass around USD 180.41billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 9.9% during the forecast period 2023 to 2032.

Specialty Generics Market Size, 2023 to 2032

Key Takeaways:

  • North America dominated the market with a share of 37.3% in 2022
  • The Asia Pacific is estimated to be the fastest-growing region over the forecast period.
  • The market is segmented into oral drugs, injectables, and others. The injectables segment held the highest share of 65.2% of the specialty generics market in 2022.
  • injectables segment is also expected to grow at the fastest growth over the forecast period.
  • The inflammatory conditions segment dominated the market with a revenue share of 28.7% in 2022
  • Oncology segment is expected to witness the significant growth over the forecast period
  • The specialty pharmacy segment dominated the market with a revenue share of 77.7% in 2022 and is expected to witness lucrative growth over the forecast period.

Specialty Generics Market Report Scope

Report Attribute Details
Market Size in 2023 USD 77.14 Billion
Market Size by 2032 USD 180.41 Billion
Growth Rate From 2023 to 2032 CAGR of 9.9%
Base Year 2022
Forecast Period 2023 to 2032 2023 to 2032
Segments Covered Type, Application, End-use, Region 
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Teva Pharmaceuticals Industries Ltd: Novartis AG (Sandoz International GmbH); Mallinckrodt; Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.); Endo Pharmaceuticals Inc.; Viatris Inc.;Fresenius Kabi Brasil Ltda; STADA Arzneimittel AG; Apotex Corp.; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd; Sun Pharmaceutical Industries Ltd.

 

The growth in the market is largely driven by increasing product approvals and the rising prevalence of complex chronic diseases, such as multiple sclerosis.

In April 2022, Dr. Reddy’s Laboratories launched a methylprednisolone sodium succinate injection in the U.S. for the treatment of patients with arthritis, blood disorders, and certain rare cancers. Furthermore, in June 2022, Elixir launched copay solutions enhancement program for the management of specialty generic medication prices. Under this program, an eligible patient receives a generic version of specialty medication at zero cost. Thus, the launch of new low-cost generic injectables and the availability of such programs is projected to fuel market growth.

Increased claim settlements and availability of specialty generic drugs increase their prescription rates due to the high safety, efficacy, and tolerability associated with them. According to the Human Resources Benefits Office University of Michigan annual report (2021), around 1,383 claims were settled for specialty generic drugs such as glatiramer acetate (Copaxone/Glatopa), teriflunomide (Aubagio), and fingolimod (Gilenya) in 2021, compared to 1,360 in 2020, with a rise of 1.7% for the treatment of patients with multiple sclerosis.

However, high costs associated with specialty generics may hamper their uptake. The lack of ability to attract patients toward drugs, marketing rights acquired by companies for off-patent drugs with no generic competition, and small target patient pool, subsequently increases the prices of products. According to the University of Michigan Prescription Drug Plan Formulary report, the average cost of specialty generic is over USD 4,500 monthly per person, compared to USD 17 to 22 for a generic prescription.

Type Insights

Based on type, the market is segmented into oral drugs, injectables, and others. The injectables segment held the highest share of 65.2% of the specialty generics market in 2022. The dominance of the injectables segment can be attributed to the benefits associated with injectables like long term effect, and immediate absorption, thus leading to higher patient compliance and acceptability.

Furthermore, injectables segment is also expected to grow at the fastest growth over the forecast period owing to increasing products approval and higher market penetration. For instance, in September 2021, Dr Reddy's Laboratories in partnership with Natco Pharma launched a generic version of Revlimid; Nat-lenalidomide & Reddy-lenalidomide approved by Health Canada for the treatment of patients with myelodysplastic syndrome and multiple myeloma in Canada. This approval provides easy access to low-cost specialty generic drugs to cancer patients, thereby, increasing prescription rate.

Application Insights

Based on application, the market is segmented into oncology, inflammatory conditions, multiple sclerosis, hepatitis C, and others. The inflammatory conditions segment dominated the market with a revenue share of 28.7% in 2022 due to increased prevalence of inflammatory conditions like rheumatoid arthritis. According to Global RA Network estimate, around 350 million people live with arthritis worldwide. In addition, according to the NHS, more than 10 million people are suffering from arthritis. Hence, the rise in prevalence of inflammatory conditions have paved the way for key players to enhance their market share in this sector. 

Oncology segment is expected to witness the significant growth over the forecast period owing to rise in disease burden of cancer and ANDA product approvals such as generic Xtandi (Enzalutamide) for treating castration-resistant prostate cancer in May 2021. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades, with a rise of 47% from 2020, owing to adoption of western lifestyle, high consumption of alcohol, smoking, poor diet choices, and physical inactivity. Growing number of cancer cases is projected to propel the demand for specialty generics.

End Use Insights

On the basis of end-use, the market has been segmented into specialty pharmacy, retail pharmacy, and hospital pharmacy. The specialty pharmacy segment dominated the market with a revenue share of 77.7% in 2022 and is expected to witness lucrative growth over the forecast period. Major specialty generic manufacturers and insurance providers choose specialty pharmacies for the distribution of products due to negligible distribution costs and easy access to medicines. According to Drug Channels Institute’s report 2021, CVS specialty, Accredo, Optum specialty pharmacy, Walgreens stores, and Humana specialty pharmacy were world’s top five specialty pharmacies.

Furthermore, low cost associated with specialty generic drug inventory offers a great return on investment on medicines compared to branded products. Factors like timely delivery, optimizing patient access, and effective distribution management of specialty pharmacies attract buyers attention to specialty pharmacy and contributes in segment growth.

Regional Insights

North America dominated the market with a share of 37.3% in 2022 owing to the presence of supportive regulatory policies regarding the approval of new products. The U.S. FDA has undertaken several initiatives to smoothen overall approval process. Thus, the U.S. FDA introduced Generic Drug User Free Amendments (GDUFA) under the Hatch-Waxman act to quicken the delivery of safe and effective low cost generic drugs to the public. As a result, the key manufacturers are constantly making efforts for commercialization of specialty generic drugs in the market. For instance, in June 2022, Amneal Pharmaceuticals Inc., launched LYVISPAH (baclofen) a specialty product approved by U.S. FDA for the indication of multiple sclerosis and other spinal cord disorders.

The Asia Pacific is estimated to be the fastest-growing region over the forecast period. The growth of region is mainly driven by high unmet low cost medicine need and launch of new generic drugs in region. In 2021, BDR Pharma launched generic version of Midostaurin with brand name of MSTARIN for the treatment of rare cancer like acute myeloid leukemia (AML).

Specialty Generics Market Share Insights

Regional expansion of product portfolio & service offerings is a key strategy adopted by players in the market. In June 2020, Sun Pharmaceutical Industries Ltd and Hikma Pharmaceuticals PLC signed an exclusive licensing and distribution agreement for Ilumya in the MEA region for the treatment of moderate to severe plaque psoriasis. This agreement offers a low-cost and equally effective specialty generic medicines to people with unmet treatment need.  Some of the key players in the global specialty generics market include: 

  • Teva Pharmaceuticals Industries Ltd
  • Viatris Inc.
  • Novartis AG (Sandoz International GmbH)
  • Hikma Pharmaceuticals PLC
  • Mallinckrodt
  • Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
  • Dr. Reddy’s Laboratories Ltd.
  • Endo Pharmaceuticals Inc.
  • Apotex Corp.
  • Sun Pharmaceutical Industries Ltd
  • Fresenius Kabi Brasil Ltda
  • STADA Arzneimittel AG

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Specialty Generics market.

By Type 

  • Injectables
  • Oral drugs
  • Others

By Application 

  • Oncology
  • Inflammatory conditions
  • Multiple sclerosis
  • Hepatitis C
  • Others

By End Use 

  • Specialty pharmacy
  • Retail pharmacy
  • Hospital pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The specialty generics market size was estimated at USD 70.19 billion in 2022 and is expected to surpass around USD 180.41billion by 2032

The global specialty generics market is expected to witness a compound annual growth rate of 9.9% from 2023 to 2032

The major factors driving market growth are the rising number of off-patent specialty drugs, increasing demand for low-cost specialty generics drugs, increasing prevalence of chronic disease, and increasing emphasis to cut down healthcare expenditure.

Some of the key players in the specialty generics market are Teva Pharmaceutical Industries Ltd; Sun Pharmaceutical Industries Ltd; Mallinckrodt; Viatris, Inc.; Fresenius Kabi Brasil Ltda; STADA Arzneimittel AG; and Novartis AG.

Chapter 1 Methodology and Scope
                  1.1 Market Segmentation
                      1.1.1 Estimates and Forecast Timeline
                  1.2 Research Methodology
                  1.3 Information Procurement
                      1.3.1 Purchased Database
                      1.3.2 nova one advisor’s Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                      1.3.5 Details of Primary Research
                  1.4 Information or Data Analysis
                      1.4.1 Data Analysis Models
                  1.5 Market Formulation & Validation
                  1.6 Model Details
                      1.6.1 Commodity Flow Analysis
                          1.6.1.1 Approach 1: Commodity Flow Approach
                          1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
                  1.7 Global Market: CAGR Calculation
                  1.8 Research Assumptions
                  1.9 List of Secondary Sources
                  1.10 List of Primary Sources
                  1.11 List of Abbreviations
                  1.12 Objectives
                      1.12.1 Objective 1
                      1.12.2 Objective 2
                      1.12.3 Objective 3
                      1.12.4 Objective 4
Chapter 2 Executive Summary
                  2.1 Market Snapshot
Chapter 3 Market Variables, Trends, & Scope
                  3.1 Market Lineage Outlook
                      3.1.1 Parent Market Outlook
                  3.2 Penetration & Growth Prospect Mapping
                  3.3 Regulatory and Reimbursement Framework
                  3.4 Market Variable Analysis
                      3.4.1 Market driver analysis
                          3.4.1.1 Rising number of off-patent specialty drugs
                          3.4.1.2 Escalating demand for low-cost generic specialty drugs
                          3.4.1.3 Increasing prevalence of chronic disease
                          3.4.1.4 Increasing emphasis to cut down healthcare expenditure
                      3.4.2 Market restraint analysis
                          3.4.2.1 High costs associated with specialty generics
                          3.4.2.2 Delay in new drug launches
                  3.5 Industry Analysis Tools
                      3.5.1 Porter's five forces analysis
                      3.5.2 PESTEL Analysis
                  3.6 Pipeline Analysis
Chapter 4 Specialty Generics Market - Segment Analysis, by Type, 2020 - 2032
                  4.1 Specialty Generics Market: Type Movement Analysis
                  4.2 Injectables
                      4.2.1 Injectables market, 2020 - 2032
                  4.3 Oral Drugs
                      4.3.1 Oral drugs market, 2020 - 2032
                  4.4 Others
                      4.4.1 Others market, 2020 - 2032
Chapter 5 Specialty generics Market - Segment Analysis, by Application, 2020 - 2032
                  5.1 Specialty Generics Market: Application Movement Analysis
                  5.2 Oncology
                      5.2.1 Oncology market, 2020 - 2032
                  5.3 Inflammatory Conditions
                      5.3.1 Inflammatory conditions market, 2020 - 2032
                  5.4 Multiple Sclerosis
                      5.4.1 Multiple sclerosis market, 2020 - 2032
                  5.5 Hepatitis C
                      5.5.1 Hepatitis C market, 2020 - 2032
                  5.6 Others
                      5.6.1 Others market, 2020 - 2032
Chapter 6 Specialty generics Market - Segment Analysis, by End-Use, 2020 - 2032
                  6.1 Specialty Generics Market: End-Use Movement Analysis
                  6.2 Specialty Pharmacy
                      6.2.1 Specialty pharmacy market, 2020 - 2032
                  6.3 Retail Pharmacy
                      6.3.1 Retail pharmacy market, 2020 - 2032
                  6.4 Hospital Pharmacy
                      6.4.1 Hospital pharmacy market, 2020 - 2032
Chapter 7 Specialty Generics Market - Regional Analysis, 2020 - 2032
                  7.1 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
                      7.1.1 North America
                          7.1.1.1 North America specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.1.2 U.S.
                              7.1.1.2.1 Key Country Dynamics
                              7.1.1.2.2 Competitive Scenario
                              7.1.1.2.3 Regulatory Framework
                              7.1.1.2.4 Reimbursement Scenario
                              7.1.1.2.5 U.S. specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.1.3 Canada
                              7.1.1.3.1 Key Country Dynamics
                              7.1.1.3.2 Competitive Scenario
                              7.1.1.3.3 Regulatory Framework
                              7.1.1.3.4 Reimbursement Scenario
                              7.1.1.3.5 Canada specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                      7.1.2 Europe
                          7.1.2.1 Europe specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.2 UK
                              7.1.2.2.1 Key Country Dynamics
                              7.1.2.2.2 Competitive Scenario
                              7.1.2.2.3 Regulatory Framework
                              7.1.2.2.4 Reimbursement Scenario
                              7.1.2.2.5 UK specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.3 Germany
                              7.1.2.3.1 Key Country Dynamics
                              7.1.2.3.2 Competitive Scenario
                              7.1.2.3.3 Regulatory Framework
                              7.1.2.3.4 Reimbursement Scenario
                              7.1.2.3.5 Germany specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.4 Spain
                              7.1.2.4.1 Key Country Dynamics
                              7.1.2.4.2 Competitive Scenario
                              7.1.2.4.3 Regulatory Framework
                              7.1.2.4.4 Reimbursement Scenario
                              7.1.2.4.5 Spain specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.5 France
                              7.1.2.5.1 Key Country Dynamics
                              7.1.2.5.2 Competitive Scenario
                              7.1.2.5.3 Regulatory Framework
                              7.1.2.5.4 Reimbursement Scenario
                              7.1.2.5.5 France specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.6 Italy
                              7.1.2.6.1 Key Country Dynamics
                              7.1.2.6.2 Competitive Scenario
                              7.1.2.6.3 Regulatory Framework
                              7.1.2.6.4 Reimbursement Scenario
                              7.1.2.6.5 Italy specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.7 Denmark
                              7.1.2.7.1 Key Country Dynamics
                              7.1.2.7.2 Competitive Scenario
                              7.1.2.7.3 Regulatory Framework
                              7.1.2.7.4 Reimbursement Scenario
                              7.1.2.7.5 Denmark specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.8 Sweden
                              7.1.2.8.1 Key Country Dynamics
                              7.1.2.8.2 Competitive Scenario
                              7.1.2.8.3 Regulatory Framework
                              7.1.2.8.4 Reimbursement Scenario
                              7.1.2.8.5 Sweden specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.2.9 Norway
                              7.1.2.9.1 Key Country Dynamics
                              7.1.2.9.2 Competitive Scenario
                              7.1.2.9.3 Regulatory Framework
                              7.1.2.9.4 Reimbursement Scenario
                              7.1.2.9.5 Norway specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                      7.1.3 Asia Pacific
                          7.1.3.1 Asia Pacific specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.2 Japan
                              7.1.3.2.1 Key Country Dynamics
                              7.1.3.2.2 Competitive Scenario
                              7.1.3.2.3 Regulatory Framework
                              7.1.3.2.4 Reimbursement Scenario
                              7.1.3.2.5 Japan specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.3 China
                              7.1.3.3.1 Key Country Dynamics
                              7.1.3.3.2 Competitive Scenario
                              7.1.3.3.3 Regulatory Framework
                              7.1.3.3.4 Reimbursement Scenario
                              7.1.3.3.5 China specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.4 India
                              7.1.3.4.1 Key Country Dynamics
                              7.1.3.4.2 Competitive Scenario
                              7.1.3.4.3 Regulatory Framework
                              7.1.3.4.4 Reimbursement Scenario
                              7.1.3.4.5 India specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.5 South Korea
                              7.1.3.5.1 Key Country Dynamics
                              7.1.3.5.2 Competitive Scenario
                              7.1.3.5.3 Regulatory Framework
                              7.1.3.5.4 Reimbursement Scenario
                              7.1.3.5.5 South Korea specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.6 Australia
                              7.1.3.6.1 Key Country Dynamics
                              7.1.3.6.2 Competitive Scenario
                              7.1.3.6.3 Regulatory Framework
                              7.1.3.6.4 Reimbursement Scenario
                              7.1.3.6.5 Australia specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.3.7 Thailand
                              7.1.3.8.1 Key Country Dynamics
                              7.1.3.8.2 Competitive Scenario
                              7.1.3.8.3 Regulatory Framework
                              7.1.3.8.4 Reimbursement Scenario
                              7.1.3.8.5 Thailand specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                      7.1.4 Latin America
                          7.1.4.1 Latin America specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.4.2 Brazil
                              7.1.4.2.1 Key Country Dynamics
                              7.1.4.2.2 Competitive Scenario
                              7.1.4.2.3 Regulatory Framework
                              7.1.4.2.4 Reimbursement Scenario
                              7.1.4.2.5 Brazil specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.4.3 Mexico
                              7.1.4.3.1 Key Country Dynamics
                              7.1.4.3.2 Competitive Scenario
                              7.1.4.3.3 Regulatory Framework
                              7.1.4.3.4 Reimbursement Scenario
                              7.1.4.3.5 Mexico specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.4.4 Argentina
                              7.1.4.4.1 Key Country Dynamics
                              7.1.4.4.2 Competitive Scenario
                              7.1.4.4.3 Regulatory Framework
                              7.1.4.4.4 Reimbursement Scenario
                              7.1.4.4.5 Argentina specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                      7.1.5 MEA
                          7.1.5.1 MEA specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.5.2 South Africa
                              7.1.5.2.1 Key Country Dynamics
                              7.1.5.2.2 Competitive Scenario
                              7.1.5.2.3 Regulatory Framework
                              7.1.5.2.4 Reimbursement Scenario
                              7.1.5.2.5 South Africa specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.5.3 Saudi Arabia
                              7.1.5.3.1 Key Country Dynamics
                              7.1.5.3.2 Competitive Scenario
                              7.1.5.3.3 Regulatory Framework
                              7.1.5.3.4 Reimbursement Scenario
                              7.1.5.3.5 Saudi Arabia specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.5.4 UAE
                              7.1.5.4.1 Key Country Dynamics
                              7.1.5.4.2 Competitive Scenario
                              7.1.5.4.3 Regulatory Framework
                              7.1.5.4.4 Reimbursement Scenario
                              7.1.5.4.5 UAE specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
                          7.1.5.5 Kuwait
                              7.1.5.5.1 Key Country Dynamics
                              7.1.5.5.2 Competitive Scenario
                              7.1.5.5.3 Regulatory Framework
                              7.1.5.5.4 Reimbursement Scenario
                              7.1.5.5.5 Kuwait specialty generics market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 Specialty Generics Market-Competitive Analysis
                  8.1 Major Deals and Strategic Alliances Analysis
                      8.1.1 New Product Launch
                      8.1.2 Mergers and Acquisitions
                      8.1.3 Partnerships and Strategic Collaborations
                      8.1.4 Conferences and Campaigns
                  8.2 Company Categorization
                      8.2.1 Market Differentiators
                      8.2.2 Innovators
                      8.2.3 Market Leaders
                  8.3 Vendor Landscape
                      8.3.1 List of key distributors and channel partners
                      8.3.2 Key customers
                  8.4 Heat map analysis
                  8.5 Public Companies
                      8.5.1 Key company market share analysis, 2021
                      8.5.2 Company Market Position Analysis
                  8.6 Private Companies
                      8.6.1 List of key emerging companies
                      8.6.2 Regional Network Map
                  8.7 Company Profiles
                      8.7.1 Teva Pharmaceutical Industries Ltd
                          8.7.1.1 Company overview
                          8.7.1.2 Financial performance
                          8.7.1.3 Product benchmarking
                          8.7.1.4 Strategic initiatives
                      8.7.2 Viatris Inc.
                          8.7.2.1 Company overview
                          8.7.2.2 Financial performance
                          8.7.2.3 Product benchmarking
                          8.7.2.4 Strategic initiatives
                      8.7.3 Novartis AG (Sandoz International GmbH)
                          8.7.3.1 Company overview
                          8.7.3.2 Financial performance
                          8.7.3.3 Product benchmarking
                          8.7.3.4 Strategic initiatives
                      8.7.4 Fresenius Kabi Brasil Ltda
                          8.7.4.1 Company overview
                          8.7.4.2 Financial performance
                          8.7.4.3 Product benchmarking
                          8.7.4.4 Strategic initiatives
                      8.7.5 Mallinckrodt
                          8.7.5.1 Company overview
                          8.7.5.2 Financial performance
                          8.7.5.3 Product benchmarking
                          8.7.5.4 Strategic initiatives
                      8.7.6 Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)
                          8.7.6.1 Company overview
                          8.7.6.2 Financial performance
                          8.7.6.3 Product benchmarking
                          8.7.6.4 Strategic initiatives
                      8.7.7 STADA Arzneimittel AG
                          8.7.7.1 Company overview
                          8.7.7.2 Financial performance
                          8.7.7.3 Product benchmarking
                      8.7.8 Endo Pharmaceuticals Inc.
                          8.7.8.1 Company overview
                          8.7.8.2 Financial performance
                          8.7.8.3 Product benchmarking
                          8.7.8.4 Strategic initiatives
                      8.7.9 Apotex Corp.
                          8.7.9.1 Company overview
                          8.7.9.2 Product benchmarking
                          8.7.9.3 Strategic initiatives
                      8.7.10 Sun Pharmaceutical Industries Ltd.
                          8.7.10.1 Company overview
                          8.7.10.2 Financial performance
                          8.7.10.3 Product benchmarking
                          8.7.10.4 Strategic initiatives
                      8.7.11 Dr. Reddy's Laboratories Ltd
                          8.7.11.1 Company overview
                          8.7.11.2 Financial performance
                          8.7.11.3 Product benchmarking
                          8.7.11.4 Strategic initiatives
                      8.7.12 Hikma Pharmaceuticals PLC
                          8.7.12.1 Company overview
                          8.7.12.2 Financial performance
                          8.7.12.3 Product benchmarking
                          8.7.12.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers